Autorisation d’accès précoce refusée à la spécialité FASENRA (benralizumab) dans l’indication « traitement des patients adultes atteints de granulomatose éosinophilique avec polyangéite et non répondeurs à mépolizumab».
See also
HAS opinions and decisions
30/08/2024
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
8NqGmtBU7eA1udut
Listen
